Vaccine History
Edward Jenner's 1796 smallpox vaccination launched modern immunization. Pasteur's rabies vaccine (1885), Salk's polio vaccine (1955), Sabin's oral polio (1961), and dozens of others followed. mRNA technology (Karikó and Weissman, with 2023 Nobel) enabled COVID-19 vaccines developed in under a year. Vaccines have prevented an estimated 154 million child deaths since 1974.
Key insights
From cowpox to mRNA in 225 years
1796: Edward Jenner uses cowpox material to immunize against smallpox. 1885: Louis Pasteur's rabies vaccine — first laboratory-developed vaccine. 1923: Diphtheria toxoid. 1953: Salk inactivated polio vaccine. 1971: First MMR (measles-mumps-rubella) combination. 1980: WHO declares smallpox eradicated. 2006: Gardasil (HPV) — first vaccine to prevent cancer. 2021: COVID-19 mRNA vaccines approved 11 months after sequence published. The acceleration is real.
The Expanded Programme on Immunization saved 154M lives
WHO's EPI launched 1974 with six diseases (diphtheria, pertussis, tetanus, measles, polio, TB). Coverage grew from ~5% to ~84% globally. Lancet 2024 estimated 154M child deaths prevented over 50 years — equivalent to half a million per year. The intervention has been called the most cost-effective public health program in history.
mRNA technology has broader applications
mRNA vaccines for COVID-19 demonstrated speed (11 months from sequence to approval) and effectiveness (90%+ initial efficacy against severe disease). The technology is now being applied to: influenza (mRNA flu vaccines in Phase 3), RSV, cancer vaccines (personalized neoantigen vaccines for melanoma, pancreatic cancer), HIV, malaria. Whether the platform scales to all these applications is the major near-term question for vaccine development.
Major vaccine milestones since 1796
Year of first major use
Key Finding: Accelerating pace through the 20th century, with mRNA enabling faster development in the 2020s.
Global DTP3 vaccination coverage 1980–2024
% of one-year-olds receiving 3 doses
Key Finding: From 22% (1980) to 84% (2024). COVID-era dip and partial recovery visible.
Methodology & caveats
How mRNA vaccines work
mRNA vaccines deliver instructions (in a lipid nanoparticle) for cells to make a specific viral protein. The immune system recognizes the protein and develops antibodies. Unlike traditional vaccines (which use weakened virus or inactivated virus or recombinant protein), mRNA vaccines don't require culturing the pathogen — speed is the major advantage. mRNA does not enter the cell nucleus or alter DNA.
Vaccine development timeline
Pre-COVID: typical vaccine development took 10-15 years. COVID-19 vaccines were developed in 11 months due to: (1) prior coronavirus research (SARS, MERS), (2) mRNA platform readiness, (3) global emergency funding, (4) parallel/accelerated Phase 1-3 trials, (5) regulatory cooperation (EUA pathways). Whether this speed can be replicated for other diseases depends on the prior research foundation.
Adjuvants and delivery
Most modern vaccines use adjuvants (substances that enhance immune response): aluminum salts, AS01 (Shingrix), MF59 (some flu vaccines), lipid nanoparticles for mRNA. Adjuvant development has been an underrated source of progress. Delivery mechanisms also matter — needle-free patches, micro-needle arrays, mucosal/oral vaccines are emerging for specific applications.